The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
An organic phosphonate that is the disoproxil ester of tenofovir. A prodrug for tenofovir, an HIV-1 reverse transcriptase inhibitor, tenofovir disoproxil is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein; Melatonin inhibits the reaction [Tenofovir results in increased expression of and results in increased activity of CASP3 protein]; Tenofovir results in increased expression of and results in increased activity of CASP3 protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein] Tenofovir results in increased expression of CASP3 mRNA
Tenofovir results in increased expression of CCL20 mRNA Tenofovir results in increased expression of and results in increased secretion of CCL20 protein
[Emtricitabine co-treated with Tenofovir] results in increased expression of CDKN1A protein Tenofovir results in increased expression of CDKN1A protein
Tenofovir results in increased secretion of HAVCR1 protein Tenofovir inhibits the reaction [cidofovir results in increased secretion of HAVCR1 protein]
Tenofovir results in decreased expression of HMOX1 protein Melatonin inhibits the reaction [Tenofovir results in decreased expression of HMOX1 protein]
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein]
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] promotes the reaction [[isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein]; [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of MPO protein
Tenofovir results in increased expression of NOS2 mRNA; Tenofovir results in increased expression of NOS2 protein Melatonin inhibits the reaction [Tenofovir results in increased expression of NOS2 protein]
Tenofovir results in increased expression of PARP1 protein Melatonin inhibits the reaction [Tenofovir results in increased expression of PARP1 protein]
Melatonin inhibits the reaction [Tenofovir affects the localization of RELA protein]; Melatonin inhibits the reaction [Tenofovir results in increased expression of and results in increased activity of RELA protein]; Melatonin inhibits the reaction [Tenofovir results in increased expression of RELA mRNA]; Tenofovir results in increased expression of and results in increased activity of RELA protein
SLC22A6 protein results in increased susceptibility to Tenofovir Probenecid inhibits the reaction [SLC22A6 protein results in increased susceptibility to Tenofovir]; SLC22A6 protein results in increased uptake of and results in increased susceptibility to Tenofovir; Tenofovir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] SLC22A6 protein results in increased import of Tenofovir
Tenofovir results in decreased expression of TNF mRNA Tenofovir results in increased expression of TNF mRNA; Tenofovir results in increased expression of TNF protein [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein]